 Eli Lilly and Co. LLY, 0.41 said Tuesday it has entered an agreement to acquire Akouos Inc. AKUS, -5.14 , a company developing a portfolio of viral gene therapies for the treatment of inner ear conditions including hearing loss, for up to 610 million in cash. Under the terms of the deal, Akouos shareholders will receive 12.50 a share in cash, plus one non-tradeable contingent value right per share that entitles the holder to receive up to an additional 3.00 in cash, for a total consideration of up to 15.50 per share in cash without interest, or an aggregate of 610 million. 